Monopar Therapeutics (MNPR) News Today $0.72 +0.07 (+10.69%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 24 at 10:49 PM | markets.businessinsider.comMonopar Therapeutics Inc: Positioned for Growth with Strategic Radiopharmaceutical Pivot and Promising Preclinical DataJuly 17, 2024 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Shares Up 4.1%June 25, 2024 | globenewswire.comMonopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24June 25, 2024 | insidertrades.comMonopar Therapeutics Inc. (NASDAQ:MNPR) COO Buys $15,175.92 in StockJune 18, 2024 | insidertrades.comInsider Buying: Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Buys 12,000 Shares of StockJune 11, 2024 | globenewswire.comMonopar and NorthStar Amend & Extend CollaborationJune 10, 2024 | globenewswire.comMonopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual MeetingJune 5, 2024 | investorplace.comPenny Stocks That Insiders Are Loading Up On: 3 Names to Watch CloselyMay 24, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Announces CFO SuccessionMay 24, 2024 | markets.businessinsider.comMonopar Therapeutics: CFO Kim Tsuchimoto To Retire - Quick FactsMay 24, 2024 | globenewswire.comMonopar Announces CFO SuccessionMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Monopar Therapeutics on Strategic Shift and Pipeline PotentialMay 9, 2024 | investorplace.comMNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024May 9, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | markets.businessinsider.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | globenewswire.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 1, 2024 | investing.comMonopar Therapeutics Inc (MNPR)April 18, 2024 | globenewswire.comMonopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingApril 16, 2024 | msn.comMonopar files patent protecting its MNPR-101 radiopharma optimization findingsApril 16, 2024 | finance.yahoo.comMonopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsApril 11, 2024 | markets.businessinsider.comBuy Rating on Monopar Therapeutics: Promising Trials and Financial Stability Highlight Growth PotentialApril 10, 2024 | globenewswire.comMonopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsMarch 28, 2024 | finance.yahoo.comMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsMarch 28, 2024 | globenewswire.comMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsMarch 6, 2024 | marketwatch.comMonpar Therapeutics Shares Rise 12% After Positive Preclinical Data for MNPR-101March 5, 2024 | markets.businessinsider.comMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramMarch 5, 2024 | globenewswire.comMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramFebruary 27, 2024 | globenewswire.comMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialFebruary 24, 2024 | cnn.comMonopar Therapeutics IncFebruary 23, 2024 | markets.businessinsider.comDow Surges Over 150 Points; AerCap Posts Upbeat EarningsFebruary 22, 2024 | msn.comWhat's Going On With Cancer-Focused Monopar Therapeutics Stock Today?February 22, 2024 | msn.comMonopar stock jumps 60% amid preclinical data for MNPR-101February 22, 2024 | finance.yahoo.comMonopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersFebruary 20, 2024 | benzinga.comCrude Oil Moves Lower; Summit Therapeutics Shares PlummetFebruary 20, 2024 | marketwatch.comMonopar Therapeutics Shares Surge on Australia Antibody-Trial ClearanceFebruary 20, 2024 | msn.comWhy Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 10:02 AM with a stated reason of "LULD pause."February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 10:02 AM with a stated reason of "LULD pause." Trading set to resume at 10:02 AM. February 20, 2024 | finance.yahoo.comMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersFebruary 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 09:02 AM with a stated reason of "LULD pause."February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. February 20, 2024 | globenewswire.comMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersFebruary 10, 2024 | reuters.comKyverna Therapeutics IncJanuary 7, 2024 | finance.yahoo.comMonopar Therapeutics Inc. (MNPR)November 9, 2023 | finance.yahoo.comMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNovember 9, 2023 | finance.yahoo.comMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNovember 9, 2023 | finance.yahoo.comMonopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical ProgramsNovember 3, 2023 | markets.businessinsider.comPromising Early Efficacy Results and Diverse Drug Development Portfolio Drive ‘Buy’ Rating for Monopar Therapeutics IncNovember 1, 2023 | finance.yahoo.comMonopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here MNPR Media Mentions By Week MNPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼1.390.61▲Average Medical News Sentiment MNPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼31▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Moleculin Biotech News Edesa Biotech News BioXcel Therapeutics News Kezar Life Sciences News Carisma Therapeutics News YS Biopharma News CalciMedica News Fortress Biotech News Lexaria Bioscience News Tempest Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.